Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Morita A, et al. Among authors: burden ad. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. Lancet. 2023. PMID: 37738999 Clinical Trial.
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A, Choon SE, Bachelez H, Anadkat MJ, Marrakchi S, Zheng M, Tsai TF, Turki H, Hua H, Rajeswari S, Thoma C, Burden AD. Morita A, et al. Among authors: burden ad. Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5. Dermatol Ther (Heidelb). 2023. PMID: 36333618 Free PMC article.
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, Hu N, Thoma C, Skalicky AM, Bachelez H. Burden AD, et al. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1327-1335. doi: 10.1111/jdv.18999. Epub 2023 Mar 18. J Eur Acad Dermatol Venereol. 2023. PMID: 36854864 Free article.
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
Burden AD, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky AM, Liberato ACS, Hu N, Thoma C, Gloede T, Kohlmann T, Lebwohl MG. Burden AD, et al. J Eur Acad Dermatol Venereol. 2024 Feb 9. doi: 10.1111/jdv.19830. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38334243
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.
Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T; BADBIR; BSTOP Study Groups; PSORT consortium. Loeff FC, et al. Among authors: burden ad. J Invest Dermatol. 2020 Nov;140(11):2129-2137. doi: 10.1016/j.jid.2020.03.957. Epub 2020 Apr 10. J Invest Dermatol. 2020. PMID: 32283057 Free article.
A genome-wide meta-analysis of palmoplantar pustulosis implicates Th2 responses and cigarette smoking in disease pathogenesis.
Hernandez-Cordero A, Thomas L, Smail A, Lim ZQ, Saklatvala JR, Chung R, Curtis CJ, Baum P, Visvanathan S, Burden AD, Cooper HL, Dunnill G, Griffiths CE, Levell NJ, Parslew R, Reynolds NJ, Wahie S, Warren RB, Wright A; APRICOT and PLUM Study Team; Simpson M, Hveem K, Barker JN, Dand N, Loset M, Smith CH, Capon F. Hernandez-Cordero A, et al. Among authors: burden ad. J Allergy Clin Immunol. 2024 May 28:S0091-6749(24)00553-0. doi: 10.1016/j.jaci.2024.05.015. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38815935 Free article.
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.
Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thaçi D, Velásquez M, Augustine M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhães R, Capon F, Bachelez H; IPC Pustular Psoriasis Working Group. Choon SE, et al. Among authors: burden ad. JAMA Dermatol. 2024 May 1. doi: 10.1001/jamadermatol.2024.0915. Online ahead of print. JAMA Dermatol. 2024. PMID: 38691347
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CEM; BADBIR and BSTOP study group. Alabas OA, et al. Br J Dermatol. 2024 Apr 17;190(5):689-700. doi: 10.1093/bjd/ljad481. Br J Dermatol. 2024. PMID: 38051972
160 results